Home Alzheimer’s Disease Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer, according to updated survival data from the phase 2 portion of the AVANOVA trial (NSGO-AVANOVA2/ENGOT-OV24; NCT02354131) that were made available as part of the 2020 ASCO Virtual Scientific Program.1

The updated results continued to support earlier findings, with an observed 66% reduction in the risk of disease progression or death (HR, 0.34; 95% CI, 0.21-0.54). The median progression-free survival (PFS) in the bevacizumab arm was 12.5 months versus 5.5 months with niraparib alone.

Statistically significant improvements in time to second progression or death, or PFS2, was demonstrated in the bevacizumab/niraparib combination arm versus the niraparib control, with corresponding medians of 20.5 versus 15.7…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments